JAK inhibition and progressive kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 24, Issue 1, 2015, Pages 88-95

  Brosius, Frank C ^a   He, John Cijiang ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic kidney disease; Janus kinase; Suppressors of cytokine signaling

Indexed keywords

BARICITINIB; DECERNOTINIB; JANUS KINASE; JANUS KINASE INHIBITOR; STAT PROTEIN;

AUTOIMMUNE DISEASE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; ENZYME INHIBITION; HIV ASSOCIATED NEPHROPATHY; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; KIDNEY POLYCYSTIC DISEASE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OBSTRUCTIVE UROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; KIDNEY DISEASE; METABOLISM;

DIABETIC NEPHROPATHIES; HUMANS; JANUS KINASES; KIDNEY DISEASES; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84918780044     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000079     Document Type: Review

References (77)

1. Li J, Gobe G. Protein kinase C activation and its role in kidney disease. Nephrology (Carlton) 2006; 11:428-434.
2. Chen J, Chen JK, Harris RC. Angiotensin II induces epit helial-to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolinmediated activation of an epidermal growth factor receptor-extracellular signalregulated kinase signaling pathway. Mol Cell Biol 2012; 32 :981-991.
3. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010; 31:541-550.
4. Lan HY, Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol 2012; 32:236-243.
5. Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013; 124:139-152.
6. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012; 36:542-550.
7. Be rthier CC, Zhang H, Schin M, et al. Enhanced expression of Janus kinasesignal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009; 58:469-477.
8. Choudhury GG, Ghosh-Choudhury N, Abboud HE. Association and direct activation of signal transducer and activator of transcription1alpha by plateletderived growth factor receptor. J Clin Invest 1998; 101:2751-2760.
9. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651-662.
10. Simon AR, Rai U, Fanburg BL, Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol 1998; 275 (6 Pt 1):C1640-C1652.
11. Marrero MB, Schieffer B, Paxton WG, et al. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995; 375:247-250.
12. Talbot JJ, Shillingford JM, Vasanth S, et al. Polycystin-1 regulates STAT activity by a dual mechanism. Proc Natl Acad Sci U S A 2011; 108:7985-7990.
13. Zhuang S. Regulation of STAT signaling by acetylation. Cell Signal 2013; 25:1924- 1931.
14. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282:20059-20063.
15. Darnell JE Jr. STATs and gene regulation. Science 1997; 277:1630-1635.
16. Stark GR, Darnell JE Jr. The JAK-STAT pathway at twenty. Immunity 2012; 36:503-514.
17. Murphy TL, Geissal ED, Farrar JD, Murphy KM. Role of the Stat4N domain in receptor proximal tyrosine phosphorylation. Mol Cell Biol 2000; 20:7121-7131.
18. Liao W, Schones DE, Oh J, et al. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 recep tor alpha-chain expression. Nat Immunol 2008; 9:1288-1296.
19. Stritesky GL, Muthukrishnan R, Sehra S, et al. The transcription factor STAT3 is required for T helper 2 cell development. Immunity 2011; 34:39-49.
20. Burchill MA, Yang J, Vogtenhuber C, et al. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3 regulatory T cells. J Immunol 2007; 178:280-290.
21. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin Immunol 2007; 19:400-408.
22. Laurence A, Tato CM, Davidson TS, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 2007; 26:371-381.
23. Cui W, Liu Y, Weinstein JS, et al. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8 T cells. Immuni ty 2011; 35:792-805.
24. Malin S, McManus S, Cobaleda C, et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat Immunol 2 010; 11:171-179.
25. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011; 12:383-390.
26. Momozawa Y, Mni M, Nakamura K, et al. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet 2011; 43:43-47.
27. Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42:508-514.
28. Flanagan SE, Haapaniemi E, Russell MA, et al. Activating germline mutations in STAT3 cause early-onset multiorgan autoimmune disease. Nat Genet 2014; 46:812-814.
29. Zhernakova A.,Stahl E.A.,Trynka G.,et al. Meta-analysis of genome-wide association studies inceliac disease and rheumatoid arthritis identifies fourteen non-HLA shared loci PLoS Genet 2011 7 e1002004.
30. Paternoster L, Standl M, Chen CM, et al. Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet 2012; 44:187-192.
31. Yu H, Pardo ll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809.
32. Siveen KS, Sikka S, Surana R, et al. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta 2014; 1845:136-154.
33. Wendt MK, Balanis N, Carlin CR, Schiemann WP. STAT3 and epithelialmesenchymal transitions in carcinomas. JAKSTAT 2014; 3:e28975.
34. Teng Y, Ross JL, Cowell JK. The involvement of JAK-STAT3 in cell motility, invasion, and metastasis. JAKSTAT 2014; 3:e28086.
35. Gotlib J. JAK inhibition in the myeloproliferative neoplasms: lessons learned from the bench and bedside. Hematology Am Soc Hematol Educ Program 2013; 2013:529-537.
36. Lee H, Zhang P, Herrmann A, et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc Natl Acad Sci U S A 2012; 109:7765-7769.
37. Sellier H, Rebillard A, Guette C, et al. How should we define STAT3 as an oncogene and as a potential target for therapy? JAKSTAT 2013; 2:e24716.
38. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 2010; 363:1117-1127.
39. Borie DC, Si MS, Morris RE, et al. JAK3 inhibition as a new concept for immune suppression. Curr Opin Investig Drugs 2003; 4:1297-1303.
40. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26:127-132.
41. O'Shea JJ, Kontzias A, Yamaoka K, et al. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013; 72 (Suppl 2):ii111-ii115.
42. Debnath B, Xu S, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J Med Chem 2012; 55:6645-6668.
43. Banes AK, Shaw S, Jenkins J, et al. Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol 2004; 286:F653-F659.
44. Wang X, Sh aw S, Amiri F, et al. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 2002; 51:3505-3509.
45. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol 2006; 290:F762-F768.
46. Woroniecka KI, Park AS, Mohtat D, et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 2011; 60:2354-2369.
47. Brosius FC 3rd, Alpers CE. New targets for treatment of diabetic nephropathy: what we have learned from animal models. Curr Opin Nephrol Hypertens 2013; 22:17-25.
48. Lu TC, Wang ZH, Feng X, et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int 2009; 76:63-71.
49. Ortiz-Munoz G, Lopez-Parra V, Lopez-Franco O, et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 2010; 21:763-772.
50. Croker BA,Kiu H,Nicholson SE. SOCS regulation of the JAK/STAT signalling pathway, Semin Cell Dev Biol, 2008, 19, 414-422.
51. Shi Y, Du C, Zhang Y, et al. Suppressor of cytokine signaling-1 ameliorates expression of MCP-1 in diabetic nephropathy. Am J Nephrol 2010; 31:380-388.
52. Hodgin JB, Nair V, Zhang H, et al. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli. Diabetes 2013; 62:299-308.
53. Zhang H, Saha J, Atkins K, Brosius F III. Podocyte JAK2 augments glomerular injury induced by diabetes and angiotensin II. J Am Soc Nephrol 2012; 23:478A.
54. Liu R, Zhong Y, Li X, et al. Role of transcription factor acetylation in diabetic kidney disease. Diabetes 2014; 63:2440-2453.
55. Liu Q, Xing L, Wang L, et al. Therapeutic effects of suppressors of cytokine signaling in diabetic nephropathy. J Histochem Cytochem 2014; 62:119-128.
56. Zhou Y, Lv C, Wu C, et al. Suppressor of cytokine signaling (SOCS) 2 attenuates renal lesions in rats with diabetic nephropathy. Acta Histochem 2014; 116:981-988.
57. Weimbs T, Olsan EE, Talbot JJ. Regulation of STATs by polycystin-1 and their role in polycystic kidney disease. JAKSTAT 2013; 2:e23650.
58. Low SH, Vasanth S, Larson CH, et al. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell 2006; 10:57-69.
59. Talbot JJ, Song X, Wang X, et al. The cleaved cytoplasmic tail of polycystin-1 regulates Src-dependent STAT3 activation. J Am Soc Nephrol 2014; 25:1737-1748.
60. Zhou J, Ouyang X, Schoeb TR, et al. Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement. J Am Soc Nephrol 2012; 23:1161-1171.
61. Karihaloo A, Koraishy F, Huen SC, et al. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 2011; 22:1809- 1814.
62. Leonhard WN, van der W al A, Novalic Z, et al. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 2011; 300:F1193-F1202.
63. Takakura A, Nelson EA, Haque N, et al. Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways. Hum Mol Genet 2011; 20:4143-4154.
64. Olsan EE, Mukherjee S, Wulkersdorfer B, et al. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease. Proc Natl Acad Sci USA 2011; 108:18067-18072.
65. Pang M, Ma L, Gong R, et al. A novel STAT3 inhibitor, S3I-201, attenuates renal interstitial fibroblast activation and interstitial fibrosis in obstructive nephropathy. Kidney international 2010; 78 :257-268.
66. Liu N, He S, Ma L, et al. Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling. PLoS One 2013; 8:e54001.
67. Koike K, Ueda S, Yamagishi S, et al. Protective role of JAK/STAT signaling against renal fibrosis in mice with unilateral ureteral obstruction. Clin Immunol 2014; 150 :78-87.
68. Yukawa K, Kishino M, Goda M, et al. STAT6 deficiency inhibits tubulointerstitial fibrosis in obstructive nephropathy. Int J Mol Med 2005; 15:225-230.
69. He JC, Husain M, Sunamoto M, et al. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 2004; 114:643-651.
70. He J C, Lu TC, Fleet M, et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol 2007; 18:93-102.
71. Gu L, Dai Y, Xu J, et al. Deletion of podocyte STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. AIDS 2013; 27:1091-1098.
72. Correa-Costa M, Azevedo H, AmanoMT, et al. Transcriptome analysis of renal ischem ia/reperfusion injury and its modulation by ischemic preconditioning or hemin treatment. PLoS One 2012; 7:e49569.
73. Nechemia-Arbely Y, Barkan D, Pizov G, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 2008; 19:1106-1115.
74. Arany I, Reed DK, Grifoni SC, et al. A novel U-STAT3-dependent mechanism mediates the deleterious effects of chronic nicoti ne exposure on renal injury. Am J Physiol Renal Physiol 2012; 302:F722-F729.
75. Ogata K, Shimamura Y, Hamada K, et al. Upregulation of HNF-1beta during experimental acute kidney injury plays a crucial role in renal tubule regeneration. Am J Physiol Renal Physiol 2012; 303:F689 -F699.
76. Susnik N, Sorensen-Zender I, Rong S, et al. Ablation of proximal tubular suppressor of cytokine signaling 3 enhances tubular cell cycling and modifies macrophage phenotype during acute kidney injury. Kidney Int 2014; 85:1357-1368.
77. Yokota N, Burne-Taney M, Racusen L, Rabb H. Contrasting roles for STAT4 and STAT6 signal transduction pathways in murine renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2003; 285:F319-F325.